| Literature DB >> 31398341 |
Lauren L Orefice1, Jacqueline R Mosko1, Danielle T Morency1, Michael F Wells2, Aniqa Tasnim1, Shawn M Mozeika1, Mengchen Ye1, Anda M Chirila1, Alan J Emanuel1, Genelle Rankin1, Ryann M Fame3, Maria K Lehtinen3, Guoping Feng2, David D Ginty4.
Abstract
Somatosensory over-reactivity is common among patients with autism spectrum disorders (ASDs) and is hypothesized to contribute to core ASD behaviors. However, effective treatments for sensory over-reactivity and ASDs are lacking. We found distinct somatosensory neuron pathophysiological mechanisms underlie tactile abnormalities in different ASD mouse models and contribute to some ASD-related behaviors. Developmental loss of ASD-associated genes Shank3 or Mecp2 in peripheral mechanosensory neurons leads to region-specific brain abnormalities, revealing links between developmental somatosensory over-reactivity and the genesis of aberrant behaviors. Moreover, acute treatment with a peripherally restricted GABAA receptor agonist that acts directly on mechanosensory neurons reduced tactile over-reactivity in six distinct ASD models. Chronic treatment of Mecp2 and Shank3 mutant mice improved body condition, some brain abnormalities, anxiety-like behaviors, and some social impairments but not memory impairments, motor deficits, or overgrooming. Our findings reveal a potential therapeutic strategy targeting peripheral mechanosensory neurons to treat tactile over-reactivity and select ASD-related behaviors.Entities:
Keywords: ASD therapeutics; GABA; autism spectrum disorders; brain development; mechanosensation; mouse genetics
Mesh:
Substances:
Year: 2019 PMID: 31398341 PMCID: PMC6704376 DOI: 10.1016/j.cell.2019.07.024
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582